Aurora Cannabis (ACB) Debuts on NYSE; Strategic Move at Helios and Matheson (HMNY); Hancock Jaffe Laboratories (HJLI) in Focus
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) recently reported that it has entered into a Sponsored Research Agreement with Texas Heart Institute for the development of CoreoGraft. The Texas Heart Institute is recognized internationally for research programs in cardiology, cardiovascular surgery, stem cell and gene therapy, and regenerative medicine, and is dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education and improved patient care.
150,000 coronary artery bypass surgeries are performed each year in the U.S., necessitating between 300,000 and 450,000 bypass grafts to revascularize the heart. Studies have shown that up to 40% of saphenous vein grafts become occluded or clogged as early as one year after bypass surgery. Hancock Jaffe's CoreoGraft is a potential alternative to saphenous vein grafting. Heart disease remains the number one killer in the U.S., accounting for over 600,000 annual deaths. Coronary heart disease is the most common form of heart disease.
Hancock Jaffe specializes in developing and manufacturing bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases.
********
Shares of Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) debuted on the New York Stock Exchange Tuesday. The company is joining a select list of Canadian cannabis producers, including Tilray Inc. (Nasdaq:TLRY), Canopy Growth Corp. (TSX:WEED) (NYSE:CGC) and Cronos Group Inc. (TSX:CRON)(Nasdaq:CRON), that are able to list on US-based exchanges.
Aurora has rapidly developed into a globally mature organization with industry leading and technologically advanced production facilities available to produce at unprecedented scale to meet the growing demand for high-quality cannabis both in Canada and abroad.
ACB closed at $7.80, down $0.89 (or -10.09%) on Tuesday. TLRY ($120.79, -1.48%), CGC ($41.01, -1.28%) and CRON ($8.34, -2.11%) also finished the regular session in negative territory
Aurora Cannabis, one of the world's largest and leading cannabis companies, is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
********
Shares of Helios and Matheson Analytics Inc. (Nasdaq:HMNY)surged more than 15% on Tuesday's trading session after the company said that its Board of Directors preliminarily has approved a plan to create a vertically integrated film production, marketing and exhibition company.
As part of the plan, the company would create a new subsidiary named MoviePass Entertainment Holdings Inc. that would take ownership of the shares of MoviePass Inc. and other film related assets held by HMNY.
Helios and Matheson Analytics is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening and consumer-centric technology.
***
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer